KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 7,352 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 7,352 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the sale, the chief executive officer now directly owns 250,800 shares in the company, valued at approximately $3,057,252. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $11.21 on Wednesday. The company has a market cap of $484.50 million, a P/E ratio of -3.30 and a beta of 0.89. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.21 and a 12 month high of $16.88. The company has a 50-day moving average of $13.16 and a 200-day moving average of $12.39.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. As a group, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.57 EPS for the current year.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Susquehanna Fundamental Investments LLC increased its stake in KalVista Pharmaceuticals by 323.5% during the second quarter. Susquehanna Fundamental Investments LLC now owns 68,526 shares of the specialty pharmaceutical company’s stock worth $807,000 after acquiring an additional 52,347 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 3,314 shares during the period. Great Point Partners LLC acquired a new position in KalVista Pharmaceuticals during the second quarter valued at approximately $15,768,000. Evoke Wealth LLC purchased a new stake in KalVista Pharmaceuticals during the second quarter worth approximately $181,000. Finally, Nicholas Investment Partners LP increased its position in shares of KalVista Pharmaceuticals by 0.9% in the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock worth $2,172,000 after acquiring an additional 1,714 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.